Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Barinthus Biotherapeutics (BRNS) Other Gross PP&E Adjustments (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Other Gross PP&E Adjustments for 7 consecutive years, with -$2.0 million as the latest value for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments rose 54.4% year-over-year to -$2.0 million; the TTM value through Mar 2026 reached -$2.0 million, up 54.4%, while the annual FY2025 figure was $5.3 million, 51.8% down from the prior year.
  • Other Gross PP&E Adjustments hit -$2.0 million in Q1 2026 for Barinthus Biotherapeutics, down from $5.3 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $11.0 million in Q4 2024 and bottomed at -$10.0 million in Q2 2022.
  • Average Other Gross PP&E Adjustments over 5 years is -$4.0 million, with a median of -$7.8 million recorded in 2024.
  • Year-over-year, Other Gross PP&E Adjustments plummeted 257.33% in 2022 and then surged 399.96% in 2023.
  • Barinthus Biotherapeutics' Other Gross PP&E Adjustments stood at -$2.4 million in 2022, then soared by 399.96% to $7.3 million in 2023, then skyrocketed by 50.45% to $11.0 million in 2024, then tumbled by 51.8% to $5.3 million in 2025, then tumbled by 137.38% to -$2.0 million in 2026.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$2.0 million, $5.3 million, and -$3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.